Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

OptiBiotix SlimBiome wins award for Weight Management Ingredient of the Year

The AIM-listed firm said the award is given to the product identified by a panel of scientific, regulatory and industry experts demonstrating leading edge research and innovation in the weight management market
cholesterol
In November 2017 SlimBiome won the award for ‘Best Functional Ingredient for Health and Well Being’ at Food Matters

OptiBiotix Health plc (LON:OPTI) has announced that its weight management ingredient SlimBiome has won the award for Weight Management Ingredient of the Year at the Vitafoods European tradeshow in Geneva.

The AIM-listed firm said the award is given to the product identified by a panel of scientific, regulatory and industry experts demonstrating leading edge research and innovation in the weight management market.

READ: OptiBiotix to bring cholesterol reduction product to India with new agreement

OptiBiotix, which develops a range of compounds to tackle obesity, high cholesterol, diabetes and skin care, said the award for Weight Management Ingredient of the Year at Vitafoods is the second industry award for SlimBiome.

In November 2017 SlimBiome won the award for ‘Best Functional Ingredient for Health and Well Being’ at Food Matters.

Stephen O’Hara, CEO of OptiBiotix, said: “Having a product with a known mechanism of action, clinical and consumer studies showing its safety and effectiveness, and the support of leading international key opinion leaders, helps give confidence to consumers in their product choice.”

He added: “Hunger free dieting is now a consumer option and we hope that the increasing number of food applications containing SlimBiome will help bring the benefits of this exciting new technology to a wider international audience."

  

View full OPTI profile View Profile

OptiBiotix Health plc Timeline

Related Articles

scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price
1528305384_Untitled-design-(3).jpg
June 06 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
laboratory
April 12 2018
Mission is to make stem cell treatments accessible and affordable to as many people as possible

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use